SciSparc Ltd. (SPRC) Form 6-K — Sep 30, 2026
SciSparc reported a $6.05M net loss for the six months ended June 30, 2026, on revenues of just $284K, with the operating loss widening 80% to $4.89M year-over-year. The company disclosed substantial doubt about its ability to continue as a going concern: it held only $4.4M in cash against negative working capital of $1.4M, and management stated cash is not sufficient to fund planned operations for a year beyond the filing date. The period was marked by strategic pivots — a second reverse split (1-for-9) in under a year, the Xylo medical IP acquisition, and NeuroThera's purchase of 54.01% of quantum firm CliniQuantum with earn-outs up to $2.5M.
Key figures
- Revenue
- 284000
- Total Assets
- 18491000
- Cash Position
- 4436000
- Reverse split
- 1-for-9 (March 4, 2026); prior 1-for-21 (July 3, 2025)
- Accumulated deficit
- 92525000
- Clinicq earnout max
- 2500000
- Neurothera stake pct
- 44.6
- Ga expense growth pct
- 52
- Rd expense growth pct
- 68
- Operating loss h1 2026
- 4887000
- Net cash used operating
- 3561000
- Negative working capital
- 1371000
- Neurothera stake value usd
- 21100000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.